Of note, median levels of the tumor biomarkers AFP, PIVKA-II, and AFPL3% were higher among HCV-HCC patients versus HCV-control patients (37.1 versus 4.3 ng/mL for AFP, 288.0 versus 22.0 mAU/mL for PIVKA-II, and 8.6% versus 0.5% for AFP-L3%; all P < 0.05) (Table 1, and Figure 2). This evidence concerns the gene AFP and hepatocellular carcinoma.